Mitsubishi UFJ Securities Holdings Co. Ltd. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 13.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 830 shares of the medical research company’s stock after selling 130 shares during the quarter. Mitsubishi UFJ Securities Holdings Co. Ltd.’s holdings in Amgen were worth $143,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in AMGN. Bank of New York Mellon Corp grew its stake in shares of Amgen by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock worth $1,403,676,000 after acquiring an additional 195,200 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Amgen by 2.5% in the 2nd quarter. Legal & General Group Plc now owns 3,721,359 shares of the medical research company’s stock worth $640,938,000 after acquiring an additional 90,615 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Amgen by 2.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 2,962,595 shares of the medical research company’s stock worth $510,248,000 after buying an additional 67,815 shares during the last quarter. UBS Asset Management Americas Inc. boosted its holdings in shares of Amgen by 3.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock worth $446,250,000 after buying an additional 81,362 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Amgen by 26.5% in the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares during the last quarter. Institutional investors and hedge funds own 78.54% of the company’s stock.

Shares of Amgen Inc. (AMGN) opened at $172.35 on Friday. Amgen Inc. has a twelve month low of $138.83 and a twelve month high of $191.10. The company has a market capitalization of $125,110.77, a PE ratio of 13.70, a P/E/G ratio of 2.50 and a beta of 1.37. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same period last year, the firm posted $3.02 earnings per share. analysts predict that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.

Amgen declared that its board has authorized a share buyback plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be given a $1.15 dividend. The ex-dividend date is Thursday, November 16th. This represents a $4.60 annualized dividend and a yield of 2.67%. Amgen’s payout ratio is 41.63%.

In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

A number of equities analysts recently weighed in on AMGN shares. Bank of America Corporation boosted their price target on shares of Amgen to $210.00 and gave the stock a “buy” rating in a report on Thursday, October 5th. Barclays PLC upped their price objective on shares of Amgen from $180.00 to $190.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Thursday, September 7th. Royal Bank of Canada started coverage on shares of Amgen in a report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective on the stock in a report on Friday, October 27th. Thirteen analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Amgen has an average rating of “Buy” and an average price target of $190.03.

TRADEMARK VIOLATION NOTICE: “Amgen Inc. (AMGN) Shares Sold by Mitsubishi UFJ Securities Holdings Co. Ltd.” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/12/amgen-inc-amgn-shares-sold-by-mitsubishi-ufj-securities-holdings-co-ltd.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.